INS and type 2 diabetes mellitus: In the COMBINE 1 trial (NCT05352815), IcoSema showed superior efficacy on HbA1c reduction compared to icodec alone (-1.55% vs. -0.89% at 52 weeks; treatment difference -0.66%, 95% CI -0.76 to -0.57) in 1291 adults with type 2 diabetes inadequately controlled on daily basal insulin (7).